SEARCH

SEARCH BY CITATION

References

  • 1
    Jarvis WR & Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 (suppl A): 19 24.
  • 2
    Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115(8): 585 90.
  • 3
    Bodey GP, Elting LS, Rodriguez S. Bacteremia caused by Enterobacter: 15 years of experience in a cancer hospital . Rev Infect Dis 1991; 13: 550 8.
  • 4
    Sanders WE & Sanders C. Enterobacter spp. pathogens poised to flourish at the turn of the century. Clin Microb Rev 1997; 10: 220 41.
  • 5
    Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211 33.
  • 6
    Sanders CC. β lactamase of gram-negative bacteria: new challenges for new drugs. Clin Infect Dis 1992; 14: 1089 99.
  • 7
    De Champs C, Sirot D, Chanal C, Poupart MC, Dumas MP, Sirot J. Concomitant dissemination of three extended-spectrum β lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother 1991; 27: 441 57.
  • 8
    De Champs C, Sauvant MP, Chanal C et al. Prospective survey of colonization and infection caused by expanded-spectrum β lactamase-producing members of the family Enterobacteriaceae in an intensive care unit. J Clin Microbiol 1989; 27: 2887 90.
  • 9
    Goldstein FW, Péan Y, Rosato A, Gertner J, Gutmann L and the Virgil'Roc Study Group. Characterization of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals. J Antimicrob Chemother 1993; 32: 595 603.
  • 10
    Rice LB, Wiley SH, Papanicolaou GA et al. Outbreak of ceftazidime resistance caused by extended-spectrum β lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990; 34: 2193 9.
  • 11
    Hibbert-Rodgers LCF, Heritage J, Gascoyne-Binzi DM et al. Molecular epidemiology of ceftazidime-resistant Enterobacteriaceae from patients on a pediatric oncology ward. J Antimicrob Chemother 1995; 36: 65 82.
  • 12
    De Champs C, Henquell C, Guelon D, Sirot D, Gazuy N, Sirot J. Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem. J Clin Microbiol 1993; 31: 123 7.
  • 13
    Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β lactamases conferring transferable resistance to newer β lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility. Rev Infect Dis 1988; 10: 867 78.
  • 14
    Arpin C, Coze C, Rogues AM, Gachie JP, Bebear C, Quentin C. Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit. J Clin Microbiol 1996; 34: 2163 9.
  • 15
    Georghiou PR, Hamill RJ, Wright CE et al. Molecular epidemiology of infections due to Enterobacter aerogenes: identification of hospital outbreak-associated strains by molecular techniques . Clin Infect Dis 1995; 20: 84 4.
  • 16
    Lucet JC, Chevret S, Decré D et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22: 430 6.
  • 17
    Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; ii: 302 6.
  • 18
    Buré A, Legrand P, Arlet G, Jarlier V, Paul G, Philippon A. Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam. Eur J Clin Microbiol Infect Dis 1988; 7: 780 2.
  • 19
    Shannon KP, King A, Phillips I, Nicolas MH, Philippon A. Importation of organisms producing broad-spectrum SHV-group β lactamases into the United Kingdom. J Antimicrob Chemother 1990; 25: 343 51.
  • 20
    Monnet DL, Biddle JW, Edwards JR et al. The National Nosocomial Infections Surveillance System. Evidence of interhospital transmission of extended-spectrum β lactam-resistant Klebsiella pneumoniae in the United States. 1986–93 . Infect Control Hosp Epidemiol 1997; 18: 492 8.
  • 21
    Struelens MJ, Byl B, Vincent JL. Antibiotic policy: a tool for controlling resistance of hospital pathogens. Clin Microbiol Infect 1999; 5(suppl 1): S19 24.
  • 22
    Jacobson KL, Cohen SH, Inciardi JF et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β lactamase-producing organisms. Clin Infect Dis 1995; 21: 1107 13.
  • 23
    Report of the Comité de L'antibiogramme de la Société Franc¸aise de Microbiologie. Clin Microbiol Infect 1996; 2(suppl 1): S46 9.
  • 24
    Sirot DL, Goldstein FW, Soussy CJ et al. Resistance to cefotaxime and seven other β lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 1992; 36: 1677 81.
  • 25
    Haertl R & Bandlow G. Epidemiological fingerprinting of Enterobacter cloacae by small-fragment restriction endonuclease analysis and pulsed-field gel electrophoresis of genomic restriction fragments. J Clin Microbiol 1993; 31: 128 33.
  • 26
    Struelens MJ, Bax R, Deplano A, Van Quint WGV, Belkum A. Concordant clonal delineation of methicillin-resistant Staphylococcus aureus by macrorestriction analysis and polymerase chain reaction genome fingerprinting. J Clin Microbiol 1993; 31: 1964 70.
  • 27
    Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233 9.
  • 28
    Kaplan E & Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457 81.
  • 29
    Cutler SJ & Ederer F. Maximum utilization of the life-table method in analyzing survival. J Chron Dis 1958; 8: 699 713.
  • 30
    Peto R & Peto J. Asymptomatically efficient rank invariant test procedures (with discussion). J R Stat Soc 1972; 135: 185 206.
  • 31
    John JF, Sharbaugh RJ, Bannister ER. Enterobacter cloacae: bacteremia, epidemiology, and antibiotic resistance . Rev Infect Dis 1982; 4: 13 28.
  • 32
    Dworzak DL, Pugsley MP, Sanders CC, Horowitz EA. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol 1987; 6: 456 9.
  • 33
    Follath F, Costa E, Thommen A, Frei R, Burdeska A, Meyer J. Clinical consequences of development of resistance to third-generation cephalosporins. Eur J Clin Microbiol 1987; 6: 446 50.
  • 34
    Snydman DR. Clinical implications of multi-drug resistance in the intensive care unit. Scand J Infect Dis 1991; 7(suppl 78): 54 63.
  • 35
    Jones RN. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn Microbiol Infect Dis 1992; 15(suppl 2): 3S 10S.
  • 36
    Ballow CH & Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15(suppl 2): 37S 42S.
  • 37
    Burwen DR, Banerjee SN, Gaynes RP. National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994; 170: 1622 5.
  • 38
    Nicolle LE. Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third-generation cephalosporins. J Hosp Infect 1988; 11: 321 7.
  • 39
    Sanders WE Jr, & Sanders CC. Inducible β lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830 8.
  • 40
    Sanders CC & Sanders WE Jr Emergence of resistance during therapy with newer β lactam antibiotics: role of inducible β lactamases and implications for the future. Rev Infect Dis 1983; 5: 639 48.
  • 41
    Olson B, Weinstein RA, Nathan C, Kabins SA. Broad-spectrum β lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance . J Antimicrob Chemother 1983; 11: 299 310.
  • 42
    Johnson MP & Ramphal R. β-Lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162: 981 3.
  • 43
    Hobson RP, MacKenzie FM, Gould IM. An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland. J Hosp Infect 1996; 33: 259 62.
  • 44
    Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353 8.
  • 45
    Antaniadou A, Giamarelllou H, Avlami A, Sarmi E. Restriction policy and strict monitoring of quinolone usage may decrease resistance in the hospital [abstract E-11]. In: Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 1997: 115.
  • 46
    White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials; expenditures, susceptibilities and clinical outcomes. Clin Infect Dis 1997; 25: 230 9.
  • 47
    Milatovic D & Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6: 234 44.
  • 48
    Sanders CC & Sanders WE Jr. Microbial resistance to newer generation β lactam antibiotics: clinical and laboratory implications. J Infect Dis 1985; 151: 399 406.
  • 49
    Weinstein RA. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. Chemoterapia 1985; 4: 110 12.